RFICs
PRODUCTS
-
Precise, Complete, and Ultimate Detection.
A premium dual energy x-ray inspection system offering outstanding detection of hard-to-find, low density contaminants, in a variety of applications. Available in standard and custom configurations
Detect Hard-to-Find Contaminants
Capable of detecting hard-to-find contaminants in a variety of applications. Offering clarity and precision in complex areas of product inspection.
Enhance Product Quality
Achieves outstanding product quality using advanced levels of foreign body detection of low-density contaminants in overlapping products.
Increase Productivity
Clever design combined with an intuitive user interface to create user-friendly systems that increase uptime and boost productivity.
-
Antibody drug conjugates (ADCs) are the emerging class of anti-cancer therapeutic drugs. ADCs combine an antibody capable of recognizing cancer cells and cytotoxic small-molecule drugs via cleavable or non-cleavable linkers, thereby transforming the 3-unit combination into a targeted therapeutic drug for cancer treatment. In recent years, ADCs have rapidly developed and there are not only more than 14 approved drugs on the market but also many investigational drugs undergoing clinical trials. Furthermore, ADCs have shown potential for treating various diseases beyond cancer, such as Autoimmune disorders, Infectious diseases, Inflammatory conditions and so on.
-
The 2048L high-resolution linescan camera with two pixel configurations and versatile line rates up to 76k lines per second.
-
Discover agile labeling and packaging services for pharmaceuticals, specializing in custom designs, regulatory support, and small to medium batch production with quick turnaround times.
-
Scientific knowledge to strategize viable and efficient drug and device development pathways to achieve successful outcomes.
WHITE PAPERS AND CASE STUDIES
-
FSP And IVD Clinical Trials
This study highlights the benefits of ProPharma's FSP services for clinical trials, including scalability, risk reduction, cost savings, and timely delivery.
-
Novel Platform For Execution Of Pragmatic Studies Boosts Cancer Trial Efficiency
Learn how Flatiron partnered with Genentech and Foundation Medicine to develop a novel platform for the execution of pragmatic studies.
-
How eSource Reduced Benchmark's Protocol Deviations By Almost 40%
Explore how a leading vaccine site network selected CRIO to help address the challenges with it's use of paper charts in collecting source data.
-
Retention And Access In NSCLC Clinical Trials
Helping participants navigate respiratory limitations, fatigue, and complex visit schedules in Non-Small Cell Lung Cancer (NSCLC) studies.
-
Drilling Down On Diversity And Feasibility
A mid-sized contract research organization (CRO) sought help with writing clinical trial diversity action plans and assessing feasibility for therapeutic areas outside its usual scope.
-
Expanding The OSD Toolbox: An Industry Approach To Adsorb Lipids Onto Powder Substrates
Explore innovative solutions for improving the solubility and bioavailability of poorly soluble compounds in solid oral dosage forms to enhance drug delivery and therapeutic effectiveness.
-
End-To-End Support To Advance Gene Therapies For Rare Retinal Diseases
Learn how expert analytical testing and clinical support helped advance a promising gene therapy for rare retinal diseases from the lab to the clinic on an expedited timeline.
-
Secondary Packaging: Inspection, Brite Stock Bottle Labeling, And Cartoning
Gain insight into a coordinated, around-the-clock approach that demonstrates how packaging efficiency can keep pace with urgent pharmaceutical launches and tight commercialization timelines.
-
Organizational Assessment For A Large MedTech Company
Explore an organizational assessment run for a medical technology company specializing in tissue repair and regeneration, and the actionable recommendations provided to facilitate future growth.
-
Accelerating Early Phase Oncology Study Development
Explore a close collaboration to co-develop a comprehensive, adaptive protocol designed to support key decisions across multiple trial phases for an innovative cancer therapy.
-
Optimizing Early-Stage Oncology
A strategic partnership enables a U.S. biotech company to address the struggles with their Phase I first-in-human oncology trial.
-
Ergomed's Solutions To The Challenges of Oncology Trials
Explore a pivotal Phase III global clinical trial investigating neoadjuvant immunotherapy for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
NEWS
-
From Everyday To Extreme, Toolant Launches Brand New Line Of Hand Tools8/15/2025
Today, toolant, a tool and accessories brand built around real-world needs, announced the launch of its brand new hand tools collection designed for automotive enthusiasts and professional car detailers alike.
-
NX Filtration And Eau d'Azur Partner For Advanced Micropollutant Treatment In Nice8/25/2025
NX Filtration, a global leader in advanced hollow fiber membrane technology, is proud to announce its collaboration with Eau d’Azur, the public company responsible for drinking water and wastewater services for the Nice Côte d'Azur Metropole.
-
Be Part of Photonics Future: CIOE 2025 Visitor Registration Live Now!4/9/2025
The 26th China International Optoelectronic Exposition (CIOE 2025) is set to take place from September 10–12, 2025, at the Shenzhen World Exhibition & Convention Center, spanning 240,000 square meters of exhibition space.
-
Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer's Drug4/28/2025
Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.
-
Ovarro Opens New Asia Pacific Headquarters8/27/2025
Water technology provider Ovarro has opened a new Asia Pacific headquarters and production facility in Selangor, Malaysia.
ABOUT
About Nutrient Removal
Nutrient removal from wastewater consists of treating wastewater to remove nitrogen and phosphorus before it reenters natural waterways. High levels of nitrogen and phosphorus in wastewater cause eutrophication, a process where excess nutrients stimulate excessive plant growth such as algal blooms and cyanobacteria. The decomposition of the algae by bacteria uses up the oxygen in the water causing other organisms to die. This creates more organic matter for the bacteria to decompose. In addition, some algal blooms can produce toxins that contaminate drinking water supplies.
As authorized by the Clean Water Act, the National Pollutant Discharge Elimination System (NPDES) permit program regulates point sources, such as municipal wastewater treatment plants, that discharge pollutants as effluent into the waters of the United States. In recent years, many of the States’ environmental bodies have lowered nutrient limits to arrest eutrophication. Maryland’s effort to protect the Chesapeake Bay and its tidal tributaries is perhaps the most notable example of nutrient removal in the US. Nutrient removal continues to be a growing area of focus for wastewater treatment throughout the world.
The removal of nitrogen and phosphorus require different nutrient removal processes. To remove nitrogen, the nitrogen is oxidized from ammonia to become nitrate through a process called nitrification. This process is then followed by denitrification where the nitrate is reduced to nitrogen gas which is released to the atmosphere and removed from the wastewater.
Nitrification is a two-step aerobic process which typically takes place in aeration tanks. Denitrification requires anoxic conditions to encourage the appropriate biological conditions to form. The activated sludge process is often used to reduce nitrate to nitrogen gas in anoxic or denitrification tanks.
Phosphorus can be removed biologically using polyphosphate accumulating organisms (PAOs) which accumulate large quantities of phosphorus within their cells and separate it from treated water. Phosphorus removal can also be achieved by chemical removal. Once removed as sludge, phosphorus may be stored in a land fill. However, many municipalities and treatment facilities are looking to resell the biosolids for use in fertilizer.